Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System

J Invest Dermatol. 2025 Jan;145(1):211-214.e1. doi: 10.1016/j.jid.2024.06.1272. Epub 2024 Jun 28.

Authors

Leore Lavin¹, Stephen Dusza¹, Shamir Geller²

Affiliations

¹ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address: [email protected].

PMID: 38945437
PMCID: PMC11625630 (available on 2026-01-01)
DOI: 10.1016/j.jid.2024.06.1272

No abstract available

Keywords: Adverse event; Biologics; Cutaneous T-cell lymphoma; Dupilumab; Pharmacovigilance.

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States